Subtilase variants and polynucleotides encoding same

Abstract

The present invention relates to subtilase variants and polynucleotides encoding them. The present invention relates to novel subtilase variants exhibiting increased stability and preferably equivalent or improved wash performance. The variants of the present invention are suitable for use in, for example, cleaning or detergent compositions, such as laundry detergent compositions and dishwashing compositions, including automatic dishwashing compositions. The invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells and methods for producing and using the variants of the invention.

Description

[0001] The present application is a divisional application of the Chinese invention patent application entitled “Subtilase variants and polynucleotides encoding the same” with application number 201580035374.X, whose international filing date is July 6, 2015 and priority date is July 4, 2014.

[0002] Reference to a sequence listing

[0003] This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference. Technical Field

[0004] The present invention relates to novel subtilase variants that exhibit increased stability and preferably equivalent or improved wash performance. These variants of the invention are suitable for use in, for example, cleaning or detergent compositions, such as laundry detergent compositions and dishwashing compositions, including automatic dishwashing compositions. The invention also relates to isolated DNA sequences encoding these variants, expression vectors, host cells, and methods for producing and using the variants of the invention. Background Art

[0005] In the detergent industry, enzymes have been used in detergent formulations for decades. Enzymes used in such formulations include proteases, lipases, amylases, cellulases, mannosidases, and other enzymes or mixtures thereof. The most commercially important enzyme is protease.

[0006] An increasing number of commercial proteases are engineered variants of naturally occurring wild-type proteases. Liquanase and (Novozymes a / s), Purafect and (Genencor International, Inc.). In addition, a variety of variants are described in the art, such as WO 2004 / 041979 (Novozymes), which describes a variety of subtilase variants that exhibit altered wash performance, thermostability, storage stability, or catalytic activity relative to the parent subtilase. These variants are suitable for use in, for example, cleaning or detergent compositions.

[0007] A variety of useful subtilase variants have been described, many of which provide improved activity, stability and solubility in different detergents.

[0008] However, a variety of factors make it advantageous to further improve proteases. Washing conditions such as temperature and pH can change over time, and many stains are still difficult to remove completely under conventional washing conditions. In addition, wash conditions can lead to enzyme inactivation (due to, for example, pH, temperature or chelation instability), resulting in a loss of wash performance during the wash cycle. Therefore, despite intensive research on protease development, there is still a need for new and improved proteases that have improved stability, particularly improved wash stability, and preferably similar or improved wash performance compared to the parent subtilase. Summary of the Invention

[0009] The present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to their parent subtilase.

[0010] In one aspect, the present invention relates to a subtilase variant having protease activity and comprising one or more substitutions selected from the group consisting of: X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X114V, X115T, X115W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, 3A, X163D, X182C, X182E, X185C, X185E, X188C, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, 2D, X212G, X212N, X216I, X216T, X216V, X217C, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261C, X261E, X261L, X261M, X261V, X261W, X261Y, X261F, X262C, X262E and X262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2.

[0011] Another aspect of the present invention relates to a subtilisin variant having protease activity comprising two or more substitutions selected from the group consisting of X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X114V, X115T, X115W, X120I , X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, 63A, X163D, X182C, X182E, X185C, X185E, X188C, , X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, 12D, X212G, X212N, X216I, X216T, X216V, X217C, , X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261C, X261E, X261L, X261M, X261V, X261W, X261Y, X261F, X262C, X262E and X262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO:2.

[0012] The present invention also relates to subtilase variants having improved stability, in particular improved in-wash stability, and preferably equivalent or improved wash performance compared to a parent or reference protease. The present invention also relates to polynucleotides encoding these subtilase variants; compositions, preferably detergent compositions, comprising the subtilase variants; the use of these compositions in cleaning processes and methods for obtaining the subtilase variants and for removing stains from surfaces.

[0013] The present invention further relates to the following embodiments:

[0014] 1. A subtilase variant of a subtilase parent, the subtilase variant having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the variant subtilase is a polypeptide having at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1.

[0015] 2. The subtilase variant according to embodiment 1, wherein the subtilase variant comprises one or more, preferably two or more, substitutions selected from the group consisting of X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X114V, X115T, X 115W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X161E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, , X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, 2A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, 256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261C, X261E, X261L, X261M, X261V, X261W, X261Y, X261F, X262C, X262E and X262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2.

[0016] 3. The subtilase variant of any one of embodiments 1 to 2, wherein the total number of alterations compared to SEQ ID NO: 1 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations.

[0017] 4. The subtilase variant of any one of embodiments 1 to 3, wherein the parent subtilase is selected from a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.

[0018] 5. The variant of any one of embodiments 1 to 4, further comprising one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K, and Q245R (numbered according to SEQ ID NO: 2).

[0019] 6. The variant of any one of embodiments 1 to 5, which variant has improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3.

[0020] 7. The variant of any one of embodiments 1 to 6, which variant has improved wash performance compared to the subtilase having SEQ ID NO: 1 when measured in an AMSA assay.

[0021] 8. A detergent composition comprising the variant according to any one of embodiments 1 to 7, wherein the detergent further comprises one or more detergent components.

[0022] 9. The detergent composition of embodiment 8, further comprising one or more additional enzymes selected from the group consisting of proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidases, haloperoxygenases, catalases, and mannanases, or any mixture thereof.

[0023] 10. The detergent composition of any one of embodiments 8 to 9, which is in the form of a bar, a uniform tablet, a tablet having two or more layers, a pouch having one or more compartments, a regular or compressed powder, granules, a paste, a gel, or a regular, compressed or concentrated liquid.

[0024] 11. Use of a detergent composition according to any one of embodiments 8 to 10 in a cleaning process such as laundry or hard surface cleaning such as dishwashing.

[0025] 12. A method for producing a subtilase variant having protease activity and having at least 25% improved stability compared to the subtilase having SEQ ID NO: 1 when measured as described in the accelerated storage stability assay of Example 3 herein, the method comprising

[0026] a. introducing into a parent subtilase one or more changes from the group consisting of: S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149 N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188 D. S188E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E, and L262Q, wherein each position corresponds to a position in SEQ ID NO: 2 and

[0027] b. Recover the variant.

[0028] definition

[0029] The term "allelic variant" means any one of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation is naturally produced by mutation and can lead to polymorphism within a population. Gene mutations can be silent (no change in the encoded polypeptide) or can encode polypeptides with altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

[0030] The term "cDNA" means a DNA molecule that can be prepared by reverse transcription from a mature, spliced ​​mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial RNA transcript is a precursor to mRNA that undergoes a series of processing steps, including splicing, before appearing as mature, spliced ​​mRNA.

[0031] The term "coding sequence" means a polynucleotide that directly specifies the amino acid sequence of a variant. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon (such as ATG, GTG, or TTG) and ends with a stop codon (such as TAA, TAG, or TGA). The coding sequence can be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.

[0032] The term "control sequence" means the nucleic acid sequence required for the expression of a polynucleotide encoding a variant of the present invention. Each control sequence can be native (i.e., from the same gene) or exogenous (i.e., from different genes) for the polynucleotide encoding the variant, or native or exogenous relative to each other. Such control sequences include, but are not limited to, leaders, polyadenylation sequences, propeptide sequences, promoters, signal peptide sequences, and transcription terminators. At a minimum, the control sequence includes a promoter and transcription and translation termination signals. For the purpose of introducing specific restriction enzyme sites that are conducive to connecting these control sequences to the coding region of the polynucleotide encoding the variant, these control sequences can be provided with multiple linkers.

[0033] The term "detergent components" is defined herein to mean the types of chemicals that can be used in detergent compositions. Examples of detergent components are surfactants, hydrotropes, builders, co-builders, chelators or chelating agents, bleaching systems or bleaching components, polymers, fabric hueing agents, fabric conditioners, foam boosters, suds suppressors, dispersants, dye transfer inhibitors, fluorescent whitening agents, perfumes, optical brighteners, bactericides, fungicides, soil-suspending agents, soil-release polymers, anti-redeposition agents, enzyme inhibitors or stabilizers, enzyme activators, antioxidants, and solubilizing agents. The detergent composition may include one or more detergent components of any type.

[0034] Unless otherwise indicated, the term "detergent composition" includes all forms of detergent compositions, such as gel, granular, liquid, paste, powder, spray or tablet compositions, including heavy-duty liquids (HDL), delicate fabric liquid detergents, liquid and / or solid laundry detergents and delicate fabric detergents; hard surface cleaning formulations for, for example, glass, wood, ceramic and metal countertops and windows; carpet cleaners; oven cleaners; fabric refreshers; fabric softeners; textile and laundry pre-spotters, as well as dishwashing detergents, such as hand dishwashing detergents, light-duty dishwashing detergents, machine dishwashing detergents; all-purpose or heavy-duty cleaners, all-purpose cleaners in liquid, gel or paste form, liquid cleaning and disinfecting agents, including antibacterial hand-washing types, cleaning bars, mouthwashes, denture cleaners, car or carpet shampoos, bathroom cleaners; hair shampoos and hair-rinses; shower gels, bubble baths; metal cleaners; as well as cleaning adjuncts, such as bleach additives and "stain-stick" or pre-treatment types.

[0035] In addition to comprising the subtilase variant of the invention, the detergent formulation may also comprise one or more additional enzymes (e.g. proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectinase lyases, xanthanases, peroxidases, haloperoxygenases, catalases and mannanases, or any mixtures thereof), and / or components such as surfactants, builders, chelators or chelating agents, bleaching systems or bleaching components, polymers, fabric conditioners, foam boosters, suds suppressors, dyes, perfumes, tarnish inhibitors, optical brighteners, bactericides, fungicides, soil suspending agents, corrosion inhibitors, enzyme inhibitors or stabilizers, enzyme activators, one or more transferases, hydrolases, oxidoreductases, bluing agents and fluorescent dyes, antioxidants and solubilizing agents.

[0036] The term "dishwashing" refers to all forms of dishwashing, such as manual or automatic dishwashing. Dishwashing includes, but is not limited to, cleaning all forms of crockery, such as plates, cups, glasses, bowls, all forms of eating utensils, such as spoons, knives, forks, and serving utensils as well as ceramic, plastic (such as melamine), metal, porcelain, glass and acrylic.

[0037] The term "dishwashing composition" refers to all forms of compositions used for cleaning hard surfaces. The present invention is not limited to any particular type of dishwashing composition or to any particular detergent.

[0038] The term "expression" includes any step involved in the production of a variant including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0039] The term "expression vector" means a linear or circular DNA molecule that includes a polynucleotide encoding a variant and is operably linked to control sequences that provide for its expression.

[0040] The term "hard surface cleaning" is defined herein as cleaning hard surfaces, where hard surfaces can include floors, tables, walls, roofs, etc., as well as the surfaces of hard objects such as cars (car washing) and tableware (dishwashing). Dishwashing includes, but is not limited to, cleaning plates, cups, glasses, bowls, and dining utensils (e.g., spoons, knives, forks), serving utensils, ceramics, plastics (e.g., melamine), metals, porcelain, glass, and acrylics.

[0041] The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.

[0042] The term "improved properties" means a characteristic associated with a subtilase variant that is improved compared to the parent subtilase, or compared to the polypeptide of SEQ ID NO: 1, or compared to a subtilase having an amino acid sequence identical to the variant but excluding the alterations in the variant. Such improved properties include, but are not limited to, wash performance, protease activity, thermal activity profile, thermal stability, pH activity profile, pH stability, substrate / cofactor specificity, improved surface properties, substrate specificity, product specificity, increased stability, improved stability under storage conditions, and chemical stability.

[0043] The term "stability" includes storage stability and stability during use, such as stability during cleaning, and reflects the stability of the subtilase variant according to the present invention as a function of time, such as how much activity the subtilase variant can retain when placed in solution, especially in a detergent solution. This stability is affected by many factors, such as pH, temperature, detergent composition, such as the amount of builder, surfactant, etc. The stability of the subtilase variant can be measured using the assay described in Example 3. The terms "improved stability" or "increased stability" are defined herein as the stability of the variant subtilase relative to the stability of the parent subtilase, relative to a subtilase having an amino acid sequence identical to the variant but excluding the changes in the variant, or relative to SEQ ID NO: 1, showing increased stability in solution. The terms "improved stability" and "increased stability" include "improved chemical stability", "detergent stability" or "improved detergent stability".

[0044] The term "improved chemical stability" is defined herein as a variant subtilase showing retention of enzymatic activity after a period of incubation in the presence of one or more chemicals, either naturally occurring or synthetic, which reduce the enzymatic activity of the parent enzyme. The improved chemical stability may also render the variants better able to catalyze reactions in the presence of such chemicals. In a particular aspect of the invention, the improved chemical stability is an improved stability in detergents, especially liquid detergents. The term "detergent stability" or "improved detergent stability" refers in particular to the improved stability of the protease activity when the subtilase variants of the invention are mixed into a liquid detergent formulation, especially a liquid detergent formulation according to Table 1, and then stored at a temperature between 15°C and 50°C, for example 20°C, 30°C or 40°C.

[0045] The term "improved thermal activity" means that a variant exhibits an altered temperature-dependent activity curve at a particular temperature relative to the temperature-dependent activity curve of the parent, relative to a subtilase having an amino acid sequence identical to the variant but excluding the changes in the variant, or relative to the protease having SEQ ID NO: 1. The thermal activity value provides a measure of the effectiveness of the variant in enhancing the catalysis of a hydrolysis reaction over a range of temperatures. A variant with greater thermal activity will result in an increase in the rate of substrate hydrolysis of an enzyme composition, thereby reducing the time required and / or lowering the enzyme concentration required for activity. Alternatively, a variant with reduced thermal activity will enhance enzymatic reactions at temperatures lower than the optimum temperature of the parent, as defined by the parent's temperature-dependent activity curve.

[0046] The term "improved wash performance" is defined herein as a subtilase variant according to the invention showing improved wash performance relative to the wash performance of the parent protease, for example by enhanced stain removal, relative to the polypeptide having SEQ ID NO: 1 or relative to a subtilase having an amino acid sequence identical to the variant but excluding the alterations in the variant. The term "wash performance" includes wash performance in laundry and, for example, dishwashing. Wash performance can be quantified as described under the definition of "wash performance" herein.

[0047] The term "isolated" means a substance in a form or setting that is not found in nature. Non-limiting examples of isolated substances include (1) any non-naturally occurring substance, (2) any substance, including but not limited to any enzyme, variant, nucleic acid, protein, peptide, or cofactor, that is at least partially removed from one or more or all of the naturally occurring components with which it is essentially associated; (3) any substance that has been artificially modified relative to the substance found in nature; or (4) any substance that has been modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). The isolated substance may be present in a fermentation broth sample.

[0048] The term "laundry" relates to both domestic and industrial laundry and means the process of treating textiles and / or fabrics with a solution comprising a detergent composition of the present invention. The laundry process can be performed, for example, using a domestic or industrial washing machine or can be performed manually.

[0049] The term "mature polypeptide" means a polypeptide in its final form after translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, autocatalytic activation, etc. In one aspect, the mature polypeptide is amino acids 1 to 269 of SEQ ID NO: 1 and amino acids 1 to 275 of SEQ ID NO: 2. It is known in the art that a host cell can produce a mixture of two or more different mature polypeptides (i.e., having a different C-terminal and / or N-terminal amino acid) expressed by the same polynucleotide.

[0050] The term "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide having protease activity.

[0051] The term "mutant" means a polynucleotide encoding a variant.

[0052] The term "nucleic acid construct" means a single-stranded or double-stranded nucleic acid molecule that is isolated from a naturally occurring gene, or that is modified to contain a segment of nucleic acid in a manner not otherwise found in nature, or that is synthetic, including one or more control sequences.

[0053] The term "operably linked" means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs the expression of the coding sequence.

[0054] The term "parent" means the protease to which the changes are made to produce the subtilase variants of the present invention. Thus, the parent is a subtilase that has an identical amino acid sequence to the variant but does not have changes at one or more (e.g., two or more) specified positions. It will be understood that the expression "having the same amino acid sequence" in this context relates to 100% sequence identity. In a specific embodiment, the parent is a protease having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any polypeptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12. Examples of parent proteases and parent subtilases are described in "Parent Proteases".

[0055] The term "protease" is defined herein as an enzyme that hydrolyzes peptide bonds. It includes any enzyme belonging to the EC 3.4 enzyme group (including each of its 13 subclasses). The EC numbering is based on the 1992 enzyme nomenclature of the NC-IUBMB Academic Press, San Diego, California, and includes publications in Eur. J. Biochem. 1994, 223, 1-5, Eur. J. Biochem. 1995, 232, 1-6, Eur. J. Biochem. 1996, 237, 1-5, Eur. J. Biochem. 1997, 250, 1-6, and Eur. J. Biochem. 1999, 264, Supplements 1-5 of 610-650. The most widely used protease in detergent industry such as clothing and dishwashing is serine protease or serine peptidase, which is a subgroup of following protease, characterized in that there is serine in the active site, and the serine forms a covalent adduct with the substrate. In addition, the feature of subtilase (and serine protease) is that in addition to serine, it also has two active site amino acid residues, i.e. histidine and aspartic acid residues. Subtilase refers to the serine protease subgroup according to Siezen et al., Protein Engineering (Protein Engng.) 4 (1991) 719-737 and Siezen et al., Protein Science (Protein Science) 6 (1997) 501-523. Subtilase can be divided into 6 subgroups, i.e., subtilisin family, thermophilic protease family, proteinase K family, lantibiotic peptidase family, Kexin family and Pyrolysin family. Term " protease activity" means proteolytic activity (EC 3.4). Proteases that can be used in detergents are primarily endopeptidases (EC 3.4.21). Several protease activity types exist: the three main activity types are: trypsin-like, in which cleavage of an amide substrate occurs at P1 after Arg or Lys; chymotrypsin-like, in which cleavage occurs at P1 after one of the hydrophobic amino acids; and elastase-like, in which cleavage occurs after Ala at P1. For the purposes of the present invention, protein activity, such as protease activity, is determined according to the procedures described in the Examples section below. In one aspect, the variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 100% of the enzymatic activity of the mature polypeptide of the parent enzyme. In a specific aspect, the subtilase variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 100% of the enzymatic activity of the polypeptide of SEQ ID NO: 1.

[0056] The term "protease activity" means proteolytic activity (EC 3.4). The proteases of the present invention are endopeptidases (EC 3.4.21). There are several types of protease activity: the three main types of activity are: trypsin-like, in which cleavage of the amide substrate occurs at P1 after Arg or Lys; chymotrypsin-like, in which cleavage occurs at P1 after one of the hydrophobic amino acids; and elastase-like, in which cleavage occurs after Ala at P1. For the purposes of the present invention, protease activity is determined according to the Suc-AAPF-pNA activity assay described in "Materials and Methods" herein. The subtilase variants of the present invention preferably have at least 20%, such as at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, and at least 100% of the protease activity of the polypeptide of SEQ ID NO: 1.

[0057] The dependency between two amino acid sequences or between two nucleotide sequences is described by parameter " sequence identity ".For purposes of the present invention, using Needleman-Wunsch algorithm (Needleman (Needleman) and Wunsch (Wunsch), 1970, J. Mol. Biol. (J.Mol.Biol.) 48:443-453) determine the sequence identity between two amino acid sequences, as in EMBOSS software package (EMBOSS:European Molecular Biology Open Software Suite (EMBOSS:The European Molecular Biology Open Software Suite), Rice (Rice) et al., 2000, Genetics Trend (Trends Genet.) 16:276-277) Needle (Needle) program, preferably executed in version 5.0.0 or later. The parameter used is gap open penalty 10, gap extension penalty 0.5, and EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle's "longest identity" annotation (obtained using the -unsimplified option) is used as the percent identity and is calculated as follows:

[0058] (Identical residues x 100) / (length of alignment - total number of gaps in the alignment).

[0059] For the purposes of the present invention, the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wengsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, supra) (preferably version 5.0.0 or later). The parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of the "longest identity" labeled Needleman (obtained using the -non-simplified option) is used as percent identity and is calculated as follows:

[0060] (Identical deoxyribonucleotides x 100) / (length of alignment - total number of gaps in the alignment).

[0061] The term "substantially pure variant" means a preparation that contains up to 10%, up to 8%, up to 6%, up to 5%, up to 4%, up to 3%, up to 2%, up to 1%, and up to 0.5% by weight of other polypeptide materials that are naturally or recombinantly associated therewith. Preferably, the variant is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.5% pure, and 100% pure, by weight of the total polypeptide material present in the preparation. These variants of the present invention are preferably present in substantially pure form. For example, this can be accomplished by preparing the variant via well-known recombinant methods or via classical purification methods.

[0062] The term "substantially pure polynucleotide" means a polynucleotide preparation that is free of other extraneous or unwanted nucleotides and is in a form suitable for use in genetically engineered polypeptide production systems. Thus, a substantially pure polynucleotide comprises by weight up to 10%, up to 8%, up to 6%, up to 5%, up to 4%, up to 3%, up to 2%, up to 1%, and up to 0.5% of other polynucleotide materials naturally or recombinantly associated with the polynucleotide. However, a substantially pure polynucleotide may comprise naturally occurring 5' and 3' untranslated regions, such as promoters and terminators. Preferably, a substantially pure polynucleotide is at least 90% pure by weight, e.g., at least 92% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, and at least 99.5% pure. These polynucleotides of the present invention are preferably present in a substantially pure form.

[0063] The term "textile" means any textile material including yarns, yarn intermediates, fibers, nonwoven materials, natural materials, synthetic materials, as well as fabrics made from these materials, such as garments, clothing and other articles. When the term fabric or clothing is used, the broad term textile is intended to be included as well.

[0064] The term "variant" means a polypeptide having protease activity that comprises an alteration (i.e., substitution, insertion, and / or deletion) at one or more (e.g., several) positions compared to a parent protease. Substitution means that the amino acid occupying a position is replaced with a different amino acid; deletion means removal of the amino acid occupying a position; and insertion means the addition of one or more (e.g., several) amino acids (e.g., 1, 2, 3, 4, or 5 amino acids) adjacent to and immediately following the amino acid occupying a position. The term subtilase variant means a variant of a subtilase parent, i.e., a subtilase variant, and is a subtilase that comprises an alteration (i.e., substitution, insertion, and / or deletion) at one or more (e.g., several) positions compared to a parent subtilase.

[0065] The term "wash performance" is used as the ability of an enzyme to remove soils present on an object to be cleaned during, for example, washing (e.g., laundry or hard surface cleaning). The improvement in wash performance can be quantified by calculating the so-called intensity value (Int) defined in the AMSA assay as described in the Materials and Methods section.

[0066] The term "wild-type subtilisin" means a protease expressed by a naturally occurring organism (e.g., a bacterium, archaea, yeast, fungus, plant, or animal found in nature). Examples of wild-type subtilisins are Savinase, i.e., amino acids 1 to 269 of SEQ ID NO 1 or BPN' (i.e., amino acids 1 to 275 of SEQ ID NO: 2).

[0067] Variant naming rules

[0068] For the purposes of the present invention, the polypeptide disclosed in SEQ ID NO: 2 (BPN ') is used to determine the corresponding amino acid residue in another protease. The amino acid sequence of another protease is aligned with the mature polypeptide disclosed in SEQ ID NO: 2, and based on the alignment, the amino acid position number corresponding to any amino acid residue in the polypeptide disclosed in SEQ ID NO: 2 is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Package, Rice et al., 2000, Trends in Genetics 16: 276-277), preferably version 5.0.0 or later. The parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.

[0069] The identification of the corresponding amino acid residue in another protease can be determined by aligning multiple polypeptide sequences using several computer programs using their corresponding default parameters, including but not limited to: MUSCLE (Multiple Sequence Comparison by Logarithmic Expectations; Version 3.5 or later; Edgar, 2004, Nucleic Acids Research 32: 1792-1797), MAFFT (Version 6.857 or later; Katoh and Kuma, 2002, Nucleic Acids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research 33: 511-518; Toh, 2007, Bioinformatics 23: 372-374; Katoh et al., 2009, Methods in Molecular Biology). Biology 537:39-64; Kato and others, 2010, Bioinformatics 26:1899-1900) and EMBOSS EMMA using ClustalW (version 1.83 or later; Thompson et al., 1994, Nucleic Acids Res. 22:4673-4680).

[0070] When other enzymes deviate from the mature polypeptide of SEQ ID NO:2 so that traditional sequence-based comparison methods cannot detect their relationship (Lindahl and Elofsson, 2000, J. Mol. Biol. 295: 613-615), other pairwise sequence comparison algorithms can be applied. Greater sensitivity in sequence-based searches can be obtained using search programs that use probabilistic representations (profiles) of polypeptide families to search databases. For example, the PSI-BLAST program generates multiple characteristic curves through an iterative database search process and is capable of detecting distant homologs (Atschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). Even greater sensitivity can be achieved if the family or superfamily of polypeptides has one or more representatives in the protein structure database. Programs such as GenTHREADER (Jones, 1999, J. Mol. Biol. 287:797-815; McGuffin and Jones, 2003, Bioinformatics 19:874-881) use information from different sources (PSI-BLAST, secondary structure predictions, structural alignment profiles, and solvation potential) as input to a neural network that predicts the structural fold of a query sequence. Similarly, the method of Gough et al., 2000, J. Mol. Biol. 313:903-919 can be used to align sequences of unknown structure with superfamily models present in the SCOP database. These alignments can then be used to generate homology models for polypeptides, and the accuracy of such models can be assessed using a variety of tools developed for this purpose.

[0071] For the protein of known structure, some tools and resources can be used for retrieving and producing structural alignment.For example, the SCOP superfamily of protein has been structurally aligned, and those alignments are accessible and downloadable. Multiple algorithms such as distance alignment matrix (Aolm (Holm) and Sander (Sander, 1998, protein (Proteins) 33:88-96) or combined extension (Shindyalov (Shindyalov) and Bern (Bourne, 1998, protein engineering (ProteinEngineering) 11:739-747) can be used to compare two or more protein structures, and the implementation of these algorithms can be used in addition to query the structural database with structure of interest, to find possible structural homologues (for example, Aolm and Parker (Park), 2000, bioinformatics (Bioinformatics) 16:566-567).

[0072] In describing the variants of the present invention, the nomenclature described below is adapted for ease of reference. Accepted IUPAC single-letter and three-letter amino acid abbreviations are employed.

[0073] replace . For amino acid substitution, the following nomenclature is used: initial amino acid, position, substituted amino acid. Thus, the histidine at position 226 is replaced by alanine and is represented as "His226Ala" or "H226A". Multiple mutations are separated by a plus sign ("+"), such as "Ile205Arg+Leu217Phe" or "I205R+L217F" representing that isoleucine (I) is replaced by arginine (R) at position 205 and position 217, and leucine (L) is replaced by phenylalanine (F). In the context of the present application, substitution is generally represented by the amino acid present in Savinase (SEQ ID NO 1) at the position corresponding to BPN' (SEQ ID NO 2). As described in "parent protease", a variety of parent proteases are suitable for preparing the disclosed variants. It will be clear to those skilled in the art that if the variant is prepared by another parent, the amino acid substitution, i.e., the amino acid before, may be different from those of Savinase (SEQ ID NO 1). This can be represented by X representing any amino acid, indicating that any original amino acid at that position can be substituted. For example, X9E means that any amino acid residue at position 9 other than E is substituted with E.

[0074] Missing For amino acid deletions, the following nomenclature is used: initial amino acid, position, * Therefore, the deletion of glycine at position 195 is represented as "Gly195 * ” or “G195 * Multiple deletions are separated by plus signs ("+"), for example, "Gly195 * +Ser9 * ” or “G195 * +S9 * ”.

[0075] insert : The insertion of another amino acid residue, such as, for example, the insertion of lysine after G195 can be represented as: Gly195GlyLys or G195GK. Alternatively, the insertion of another amino acid residue, such as the insertion of lysine after G195 can be represented as: *195aK. When more than one amino acid residue is inserted, for example, Lys and Ala after G195 can be represented as: Gly195GlyLysAla or G195GKA. In such cases, the inserted amino acid residue(s) can also be numbered by adding lowercase letters to the amino acid residue position number preceding the inserted amino acid residue(s), in this example: * 195aK * 195bA. In the above example, the sequence 194 to 196 is thus: 194 195 196

[0077] Savinase AGL

[0078] 194 195 195a 195b 196

[0079] Variant AGKAL

[0080] Where the substitution and insertion occur at the same position, this may be represented as S99SD+S99A, or abbreviated as S99AD. The same modification may also be represented as S99A+ * 99aD.

[0081] In cases where an amino acid residue identical to an existing amino acid residue is inserted, degeneracy in the nomenclature is evident. If, for example, a glycine is inserted after the glycine in the above example, it would be represented as G195GG or *195GaG. For the following changes, the same actual change could also be represented simply as A194AG or * 194aG, from: 194 195 196

[0083] Savinase AGL

[0084] arrive:

[0085] 194 195 195a 196

[0086] Variant AGGL

[0087] 194 194a 195 196

[0088] Such cases will be obvious to the skilled person, and therefore the expression G195GG and corresponding expressions inserted in this manner are intended to include such equivalent degenerate expressions.

[0089] Multiple changes: Variants comprising multiple alterations are separated by plus signs ("+"), e.g., "Arg170Tyr+Gly195Glu" or "R170Y+G195E" represent substitutions of arginine and glycine at positions 170 and 195, respectively, by tyrosine and glutamic acid. Alternatively, spaces or commas may separate multiple alterations, e.g., R170Y G195E or R170Y, G195E, respectively.

[0090] Different changes : When different changes can be introduced at one position, these changes are separated by a comma, for example, "Arg170Tyr,Glu" represents that the arginine at position 170 is replaced by tyrosine or glutamic acid. Thus, "Tyr167Gly,Ala+Arg170Gly,Ala" represents the following variants:

[0091] “Tyr167Gly+Arg170Gly”, “Tyr167Gly+Arg170Ala”, “Tyr167Ala+Arg170Gly”, and “Tyr167Ala+Arg170Ala”.

[0092] Alternatively, the various alterations or optional substitutions may be indicated by brackets, for example Arg170[Tyr, Gly] or Arg170{Tyr, Gly} or abbreviated as R170[Y, G] or R170{Y, G}.

[0093] Amino acid position / residue numbering

[0094] Unless otherwise indicated, amino acid numbering used herein corresponds to the amino acid sequence of subtilisin BPN' (BASBPN). The amino acid sequence of subtilisin BPN' is amino acids 1 to 275 of SEQ ID NO: 2 (Siezen et al., 1991, Protein Engineering 4: 719-737).

[0095] Table 1 of WO 89 / 06279 shows the mature polypeptide of the subtilisin BPN' (BASBPN) sequence (sequence c in Table 1) and subtilisin 309 from Bacillus lentus (also known as (BLSAVI)) (sequence a in Table 1) alignment of the mature polypeptides. DETAILED DESCRIPTION

[0096] The present invention relates to subtilase variants having improved stability compared to their parent subtilase. A particularly preferred aspect of the present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to their parent subtilase. Preferably, the subtilase variant according to the present invention has at least 25% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein. A preferred aspect of the present invention relates to variants of a subtilase parent, i.e. a "subtilase variant" having protease activity and having at least 25% improved stability compared to the parent subtilase when measured as described in the accelerated storage stability assay in Example 3, wherein the subtilase variant comprises one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43 L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V14 7W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185 E. S188C, S188D, S188E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206 V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T , M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO:2.

[0097] Each of the above single mutations increases stability compared to the parent subtilase. Thus, introduction of any of the above substitutions into the subtilase parent provides increased stability.

[0098] As mentioned above, each single mutation increased stability compared to the parent subtilase, and even further as can be seen in Example 4, adding two, three, four, etc. of these mutations increased stability. Thus, a preferred aspect of the present invention relates to variants of a subtilase parent, wherein the subtilase variant has an improved stability of at least 25% compared to the parent subtilase, wherein the subtilase variant comprises two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S72V, 8D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E , G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S1 88E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206 L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M 222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO:2.

[0099] The parent protease is preferably selected from a protease having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any polypeptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0100] The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 1. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 2. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 3. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 4. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 5.The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 6. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 7. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 8. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 9. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 10.The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 11. The subtilase variant is preferably selected from subtilase variants having at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence of SEQ ID NO: 12.

[0101] One aspect of the present invention relates to variants of a subtilase parent, wherein the subtilase variant has at least 25% improved stability compared to the parent subtilase, wherein the subtilase variant comprises two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V1 04F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G16 0D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E , Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M2 22R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E, and L262Q, wherein each position corresponds to SEQ NO: 12, and wherein the subtilase variant has at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide having SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0102] A preferred aspect of the invention relates to subtilase variants having protease activity and at least 50% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variants comprise one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161 E. S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N2 04V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225 A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2.

[0103] Another preferred aspect of the invention relates to subtilase variants having protease activity and at least 75% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variants comprise one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161 E. S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N2 04V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225 A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2.

[0104] Another preferred aspect of the invention relates to subtilase variants having protease activity and at least 100% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variants comprise one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W , H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S16 1E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N 204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A , S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P22 5A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2.

[0105] Another preferred aspect of the present invention relates to subtilase variants having protease activity and having at least 25%, such as at least 30%, such as at least 35%, such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 100%, such as at least 105%, such as at least 110%, such as at least 115% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variants comprise one or more selected from the group consisting of Replaced by, the group consisting of: S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q 206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L21 7C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO:2.

[0106] The stability of the improvement in this context is measured by the improvement coefficient as described in Example 4 herein. The activity decline during incubation with detergent is assumed to be exponential. From the linear regression of Log (activity) to incubation time (0,1-4 and 20-25 hours), the half-life (T1 / 2) is found, and the half-life improvement coefficient (T1 / 2IF) is calculated as the half-life of the subtilase variant relative to the half-life of the reference enzyme. The reference enzyme in Example 3 is Savinase (SEQ ID NO 1) with N76D mutation (SEQ ID NO 3). The reference enzyme in Examples 5 and 6 is SEQ ID NO 8. The reference enzyme is preferably the parent subtilisin, in this way, the contribution of each mutation can be measured. The term improved stability in this context is the improvement coefficient calculated as above, expressed as percentage improvement. Therefore, an improvement of 25% corresponds to an improvement coefficient of 1.25, etc.

[0107] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0108] One aspect of the present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase having SEQ ID NO: 2 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variants have protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 2 2, the subtilase variant comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A114V, I115T, I115W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161C, S161E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191N, S204D , S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N21 2A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P2 255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261C, F261E, F261L, F261M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant has at least 80% identity to SEQ ID NO: 2.

[0109] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO 3 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0110] A preferred aspect relates to a subtilase variant having protease activity, wherein the subtilase comprises the substitution N76D and one or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61D, I72A, I72V, S78D, S78N, V104F, V104P, V104 T, V104Y, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P , S161C, S161Y, S161E, I162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191N, A 194D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y2 09W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P22 5S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261D, N261C, N261E, N261L, N261M, N261R, N261V, N261W, N261Y, N261F, L262Y, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2.

[0111] Another aspect of the invention relates to a subtilase variant having protease activity comprising the substitution N76D and one or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V105 04Y, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S1 61C, S161Y, S161E, I162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191N, A19 4D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y20 9W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P225 S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261D, N261C, N261E, N261L, N261M, N261R, N261V, N261W, N261Y, N261F, L262Y, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0112] Another aspect of the invention relates to a subtilase variant having protease activity comprising the substitution N76D and two or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V 104Y, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S1 61C, S161Y, S161E, I162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191N, A19 4D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y20 9W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P225 S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261D, N261C, N261E, N261L, N261M, N261R, N261V, N261W, N261Y, N261F, L262Y, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0113] A preferred aspect of the invention relates to a subtilase variant having protease activity comprising the substitution N76D and one or more, preferably two or more, substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, N18S, S49T, G53A, G53L, G61D, S78N, V104P, V104T, V104Y, V149Q, S161Y, I162L, A194D, A194E, V205L, Y209L, M222A, P225S, V244H, N248H, T255Q, T260A, N261R and L262Y, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0114] Another preferred aspect of the present invention relates to a subtilase variant having protease activity comprising the substitution N76D and one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G1 15T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S 161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N 204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0115] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 4 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0116] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 5 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0117] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 6 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0118] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 7 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0119] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 8 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; ...

[0120] A preferred aspect of the present invention relates to a subtilase variant having protease activity, wherein the subtilase variant comprises one or more, preferably two or more, substitutions selected from the group consisting of S3V, S3Y, S9M, P40E, N43E, N43D, R45E, H120I, H120D, A133E, Q182E, S188T, V205I, Q206E, S212D, N218D, A228S, Q236E, Q245R, S259D, L262Y and A270G, compared to SEQ ID NO: 8, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 8.

[0121] Another preferred aspect of the present invention relates to a subtilase variant having protease activity, wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S3V, S3Y, S9M, S9C, S9D, S9E, S9Q, P40E, N43E, N43D, N43A, N43C, N43L, N43R, N43W, R45E, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120D, H120I, H120T, H120V, P129D, A133E, V147W, V149C, 149N, A158E, G160D, G160P, S161 C. S161E, S163A, S163D, Q182E, Q182C, Q182E, N185C, N185E, S188T, S188C, S188D, S188E, Q191N, N 204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S21 2D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, N218D, M222C, M222R, P225A, A228S, Q236E, Q245R, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262Y, L262C, L262E, L262Q and A270G, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0122] One aspect of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 9 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120 T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V20 5I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D , S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T2 The subtilase variant comprises: a subtilase comprising: a 5-amino acid sequence of the subtilisinase; a 5-amino acid sequence of the subtilisinase comprising: ...

[0123] One aspect of the present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase having SEQ ID NO: 10 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variants have protease activity and ... have at least 25% improved stability compared to the subtilase having SEQ ID NO: 10 10, the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A114V, I115T, I115W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161C, S161E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191N, S204 D. S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N21 2A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P2 255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261C, F261E, F261L, F261M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant has at least 80% identity to SEQ ID NO: 10.

[0124] One aspect of the present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase having SEQ ID NO: 11 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variants have protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 11 11, the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A114V, I115T, I115W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161C, S161E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191N, S204 D. S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N21 2A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P2 255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261C, F261E, F261L, F261M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant has at least 80% identity to SEQ ID NO: 11.

[0125] One aspect of the present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase having SEQ ID NO: 12 when measured in the accelerated storage stability assay in Example 3 as described herein, and wherein the subtilase variants have protease activity and ... have at least 25% improved stability compared to the subtilase having SEQ ID NO: 12 12, the subtilase variant comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A114V, I115T, I115W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161C, S161E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191N, S204 D. S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N21 2A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P2 255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261C, F261E, F261L, F261M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant has at least 80% identity to SEQ ID NO: 12.

[0126] In one embodiment the subtilase variant has improved stability, in particular improved storage stability, compared to the mature polypeptide of the parent subtilase or to the polypeptide of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12. In a preferred embodiment the subtilase variant has improved stability, in particular improved storage stability, and equivalent or improved wash performance compared to the parent subtilase polypeptide or to the polypeptide of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12.

[0127] In one embodiment the present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the parent subtilase when measured in the accelerated storage stability assay of Example 3 herein, wherein the subtilase variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N4 3C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129 D. V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q 206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N21 8T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is

[0128] a) a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of the parent subtilase; or

[0129] b) a polypeptide encoded by a polynucleotide having at least 60% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.

[0130] In embodiments, the subtilase variant has at least 65% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 70% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 75% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 80% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 85% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 90% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 93% but less than 100% sequence identity with the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 95% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 96% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 97% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In embodiments, the subtilase variant has at least 98% but less than 100% sequence identity to the mature polypeptide of the parent subtilase.

[0131] In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 65% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 70% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 75% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 80% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 85% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 90% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 93% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 95% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 96% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide having at least 97% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In embodiments, the subtilase variant is encoded by a polynucleotide having at least 98% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.

[0132] In one aspect, the total number of alterations in the subtilase variant is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations compared to the parent subtilase. In another aspect, the total number of alterations in the parent subtilase is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.

[0133] The parent subtilase can be any subtilase. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 1. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 2. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 3. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 4. In one aspect, the parent subtilase is amino acids 1 to 270 of SEQ ID NO: 5. In one aspect, the parent subtilase is amino acids 1 to 270 of SEQ ID NO: 6. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 7. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 8. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 9. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 10. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 11. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 12.

[0134] One embodiment of the present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO 1 when measured in the accelerated storage stability assay of Example 3 herein, wherein the variant comprises one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G116 5W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S 161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212 A. S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P22 5A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0135] In embodiments, the subtilase variant has at least 65% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 70% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 75% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 80% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 85% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 90% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 93% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 95% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 96% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 97% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In embodiments, the subtilase variant has at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1.

[0136] In one aspect, the total number of alterations in the polypeptide of SEQ ID NO: 1 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, and most preferably between 3 and 8 alterations. In another aspect, the total number of alterations in the polypeptide of SEQ ID NO: 1 is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.

[0137] In one embodiment, the subtilase variant has improved stability, particularly improved storage stability, compared to the polypeptide of SEQ ID NO: 1. In a preferred embodiment, the subtilase variant has improved stability, particularly improved in-wash stability, and / or equivalent or improved wash performance compared to the polypeptide of SEQ ID NO: 1.

[0138] In one embodiment the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12 when measured in the accelerated storage stability assay of Example 3 herein, wherein the variant comprises one or more substitutions selected from the group consisting of X9C, 9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X114V, X115T, X115W, 120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, E, X163A, X163D, X182C, X182E, 205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, 2D, X212G, X212N, X216I, X216T, X216V, X217C, or X262C, wherein each position corresponds to a position in the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0139] In embodiments, the subtilase variant has at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 81%, such as at least 82%, such as at least 83%, such as at least 84%, such as at least 85%, such as at least 86%, such as at least 87%, such as at least 88%, such as at least 89%, such as at least 90%, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, such as at least 99%, but less than 100% sequence identity to any polypeptide comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0140] In one aspect, the total number of alterations in any parent polypeptide selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations. On the other hand, the total number of alterations in any parent polypeptide selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 is 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 alterations.

[0141] In one embodiment the subtilase variant has improved stability, particularly improved storage stability, compared to any polypeptide having SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12. In one embodiment the subtilase variant has improved stability, particularly improved in-wash stability, and / or equivalent or improved wash performance, compared to any polypeptide having SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0142] In a particular embodiment, the parent subtilase is any of the subtilases SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, and any particularly preferred stabilizing mutations are selected from the group consisting of the following substitutions: S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G115W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206

[00155] In one embodiment, the present invention provides a stabilizing effect of at least one stabilizing mutation, wherein the stabilizing effect is significantly improved. The present invention also provides a stabilizing effect of at least one stabilizing mutation, wherein the stabilizing effect is significantly improved. In another embodiment, the present invention provides a stabilizing effect of at least one stabilizing mutation, wherein the stabilizing effect is significantly improved. In another embodiment, the present invention provides a stabilizing effect of at least one stabilizing mutation, wherein the stabilizing effect is significantly improved.Thus, a particularly preferred embodiment of the present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase parent when measured in the accelerated storage stability assay of Example 3 herein, wherein the subtilase variant comprises two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G115W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261C, N261E, N261L, N261V, N261Y, N261W, N261F, L262C, L262E, and L262Q, wherein each position corresponds to SEQ The invention further comprises the step of: encoding a subtilase variant comprising: a polypeptide ...

[0143] Even more specifically preferred stabilizing mutations are selected from the group consisting of the following substitutions: S9E, N43R, H120V, Q182E, Q191N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261E, N261W and L262E. Accordingly, another preferred embodiment of the present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the parent subtilase when measured in the accelerated storage stability assay of Example 3 herein, wherein the variant comprises one or more substitutions selected from the group consisting of S9E, N43R, H120V, Q182E, Q191N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261E, N261W and L262E, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, wherein the subtilase variant is a polypeptide having at least 60% identity to the parent protease, and wherein the parent subtilase is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12.

[0144] In one aspect of the invention, the subtilase variant comprises or consists of one or more, preferably two or more, of the substitutions in Table 1, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one aspect of the invention, the subtilase variant comprises or consists of one or more, preferably two or more, of the substitutions in Table 1, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% identity to the amino acid sequence of SEQ ID NO: 1. In one aspect of the invention, the subtilase variant comprises an amino acid sequence comprising one or more, preferably two or more substitutions compared to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the substitutions are selected from the substitutions in Table 1, and wherein the positions correspond to the corresponding positions of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or to any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12. In a preferred embodiment, the subtilase variant has improved stability, in particular improved storage stability, and equivalent or improved wash performance, compared to the polypeptide of SEQ ID NO: 1 or to any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0145] Table 1: Subtilase variants SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11 or SEQ ID NO: 12 + one or more mutations listed below

[0146] S9C S163D S216V S9D S163A L217C S9E Q182C L217M Q9Q Q182E N218T N43A N185C M222C N43C N185E M222R N43L S188C P225A N43R S188D T255C N43W S188E T255E I72A Q191N S256A I72V N204D S256C S78D N204V S256D V104F V205I S256V A114V Q206C S256Y G115T Q206E S259D G115W Q206I T260E H120I Q206K T260P H120T Q206T N261C H120V Q206V N261E P129D Q206W N261L V147W Q206L N261M V149C Y209W N261V V149N S212A N261Y A158E S212D N261F G160D S212G N261W G160P S212N L262C S161C S216I L262E S161E S216T L262Q

[0147] In one embodiment, the parent subtilase is a subtilase having the amino acid sequence of SEQ ID NO: 1. Thus, in one embodiment, the subtilase variant comprises or consists of the substitution S9C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0148] In one embodiment the subtilase variant comprises or consists of the substitution S9D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0149] In one embodiment the subtilase variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0150] In one embodiment the subtilase variant comprises or consists of the substitution S9Q in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0151] In one embodiment the subtilase variant comprises or consists of the substitution N43A in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0152] In one embodiment the subtilase variant comprises or consists of the substitution N43C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0153] In one embodiment the subtilase variant comprises or consists of the substitution N43L in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0154] In one embodiment the subtilase variant comprises or consists of the substitution N43R in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0155] In one embodiment the subtilase variant comprises or consists of the substitution N43W in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0156] In one embodiment the subtilase variant comprises or consists of the substitution I72A in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0157] In one embodiment the subtilase variant comprises or consists of the substitution I72V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0158] In one embodiment the subtilase variant comprises or consists of the substitution S78D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0159] In one embodiment the subtilase variant comprises or consists of the substitution V104F in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0160] In one embodiment the subtilase variant comprises or consists of the substitution G115T in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0161] In one embodiment the subtilase variant comprises or consists of the substitution G115W in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0162] In one embodiment the subtilase variant comprises or consists of the substitution H120I in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0163] In one embodiment the subtilase variant comprises or consists of the substitution H120T in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0164] In one embodiment the subtilase variant comprises or consists of the substitution H120V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0165] In one embodiment the subtilase variant comprises or consists of the substitution P129D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0166] In one embodiment the subtilase variant comprises or consists of the substitution V147W in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0167] In one embodiment the subtilase variant comprises or consists of the substitution V149C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0168] In one embodiment the subtilase variant comprises or consists of the substitution V149N in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0169] In one embodiment the subtilase variant comprises or consists of the substitution A158E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0170] In one embodiment the subtilase variant comprises or consists of the substitution G160D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0171] In one embodiment the subtilase variant comprises or consists of the substitution G160P in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0172] In one embodiment the subtilase variant comprises or consists of the substitution S161C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0173] In one embodiment the subtilase variant comprises or consists of the substitution S161E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0174] In one embodiment the subtilase variant comprises or consists of the substitution S163A in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0175] In one embodiment the subtilase variant comprises or consists of the substitution S163D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0176] In one embodiment the subtilase variant comprises or consists of the substitution Q182C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0177] In one embodiment the subtilase variant comprises or consists of the substitution Q182E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0178] In one embodiment the subtilase variant comprises or consists of the substitution N185C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0179] In one embodiment the subtilase variant comprises or consists of the substitution N185E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0180] In one embodiment the subtilase variant comprises or consists of the substitution S188C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0181] In one embodiment the subtilase variant comprises or consists of the substitution S188D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0182] In one embodiment the subtilase variant comprises or consists of the substitution S188E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0183] In one embodiment the subtilase variant comprises or consists of the substitution Q191N in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0184] In one embodiment the subtilase variant comprises or consists of the substitution N204D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0185] In one embodiment the subtilase variant comprises or consists of the substitution N204V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0186] In one embodiment the subtilase variant comprises or consists of the substitution V205I in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0187] In one embodiment the subtilase variant comprises or consists of the substitution Q206C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0188] In one embodiment the subtilase variant comprises or consists of the substitution Q206E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0189] In one embodiment the subtilase variant comprises or consists of the substitution Q206I in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0190] In one embodiment the subtilase variant comprises or consists of the substitution Q206K in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0191] In one embodiment the subtilase variant comprises or consists of the substitution Q206T in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0192] In one embodiment the subtilase variant comprises or consists of the substitution Q206V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0193] In one embodiment the subtilase variant comprises or consists of the substitution Q206W in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0194] In one embodiment the subtilase variant comprises or consists of the substitution Q206L in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0195] In one embodiment the subtilase variant comprises or consists of the substitution Y209W in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0196] In one embodiment the subtilase variant comprises or consists of the substitution S212A in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0197] In one embodiment the subtilase variant comprises or consists of the substitution S212D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0198] In one embodiment the subtilase variant comprises or consists of the substitution S212G in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0199] In one embodiment the subtilase variant comprises or consists of the substitution S212N in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0200] In one embodiment the subtilase variant comprises or consists of the substitution S216I in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0201] In one embodiment the subtilase variant comprises or consists of the substitution S216T in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0202] In one embodiment the subtilase variant comprises or consists of the substitution S216V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0203] In one embodiment the subtilase variant comprises or consists of the substitution L217C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0204] In one embodiment the subtilase variant comprises or consists of the substitution L217M in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0205] In one embodiment the subtilase variant comprises or consists of the substitution N218T in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0206] In one embodiment the subtilase variant comprises or consists of the substitution M222C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0207] In one embodiment the subtilase variant comprises or consists of the substitution M222R in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0208] In one embodiment the subtilase variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0209] In one embodiment the subtilase variant comprises or consists of the substitution T255C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0210] In one embodiment the subtilase variant comprises or consists of the substitution T255E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0211] In one embodiment the subtilase variant comprises or consists of the substitution S256A in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0212] In one embodiment the subtilase variant comprises or consists of the substitution S256C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0213] In one embodiment the subtilase variant comprises or consists of the substitution S256D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0214] In one embodiment the subtilase variant comprises or consists of the substitution S256V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0215] In one embodiment the subtilase variant comprises or consists of the substitution S256Y in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0216] In one embodiment the subtilase variant comprises or consists of the substitution S259D in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0217] In one embodiment the subtilase variant comprises or consists of the substitution T260E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0218] In one embodiment the subtilase variant comprises or consists of the substitution T260P in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0219] In one embodiment the subtilase variant comprises or consists of the substitution N261C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0220] In one embodiment the subtilase variant comprises or consists of the substitution N261E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0221] In one embodiment the subtilase variant comprises or consists of the substitution N261L in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0222] In one embodiment the subtilase variant comprises or consists of the substitution N261M in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0223] In one embodiment the subtilase variant comprises or consists of the substitution N261V in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0224] In one embodiment the subtilase variant comprises or consists of the substitution N261W in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0225] In one embodiment the subtilase variant comprises or consists of the substitution N261Y in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0226] In one embodiment the subtilase variant comprises or consists of the substitution N261F in the polypeptide of SEQ ID NO: 1, wherein each position corresponds to a position of SEQ ID NO: 2.

[0227] In one embodiment the subtilase variant comprises or consists of the substitution L262C in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0228] In one embodiment the subtilase variant comprises or consists of the substitution L262E in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0229] In one embodiment the subtilase variant comprises or consists of the substitution L262Q in the polypeptide of SEQ ID NO: 1, wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0230] In a preferred embodiment of the present invention, the variant is a polypeptide having a substitution according to the present invention and having an amino acid sequence that is at least 60% identical to SEQ ID NO: 1. Thus, in one embodiment, the subtilase variant comprises or consists of the substitution S9C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0231] In an embodiment the subtilase variant comprises or consists of the substitution S9D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0232] In an embodiment the subtilase variant comprises or consists of the substitution S9E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0233] In an embodiment the subtilase variant comprises or consists of the substitution S9Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0234] In an embodiment the subtilase variant comprises or consists of the substitution N43A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0235] In an embodiment the subtilase variant comprises or consists of the substitution N43C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0236] In an embodiment the subtilase variant comprises or consists of the substitution N43L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0237] In an embodiment the subtilase variant comprises or consists of the substitution N43R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0238] In an embodiment the subtilase variant comprises or consists of the substitution N43W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0239] In an embodiment the subtilase variant comprises or consists of the substitution I72A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0240] In an embodiment the subtilase variant comprises or consists of the substitution I72V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0241] In an embodiment the subtilase variant comprises or consists of the substitution S78D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0242] In an embodiment the subtilase variant comprises or consists of the substitution V104F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0243] In an embodiment the subtilase variant comprises or consists of the substitution A114V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0244] In an embodiment the subtilase variant comprises or consists of the substitution G115T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0245] In an embodiment the subtilase variant comprises or consists of the substitution G115W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0246] In an embodiment the subtilase variant comprises or consists of the substitution H120I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0247] In an embodiment the subtilase variant comprises or consists of the substitution H120T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0248] In an embodiment the subtilase variant comprises or consists of the substitution H120V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0249] In an embodiment the subtilase variant comprises or consists of the substitution P129D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0250] In an embodiment the subtilase variant comprises or consists of the substitution V147W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0251] In an embodiment the subtilase variant comprises or consists of the substitution V149C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0252] In an embodiment the subtilase variant comprises or consists of the substitution V149N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0253] In an embodiment the subtilase variant comprises or consists of the substitution A158E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0254] In an embodiment the subtilase variant comprises or consists of the substitution G160D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0255] In an embodiment the subtilase variant comprises or consists of the substitution G160P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0256] In an embodiment the subtilase variant comprises or consists of the substitution S161C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0257] In an embodiment the subtilase variant comprises or consists of the substitution S161E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0258] The subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence. In one embodiment, the subtilase variant comprises or consists of the substitution S163A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence having SEQ ID NO: 1.

[0259] In an embodiment the subtilase variant comprises or consists of the substitution S163D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0260] In an embodiment the subtilase variant comprises or consists of the substitution Q182C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0261] In an embodiment the subtilase variant comprises or consists of the substitution Q182E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0262] In an embodiment the subtilase variant comprises or consists of the substitution N185C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0263] In an embodiment the subtilase variant comprises or consists of the substitution N185E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0264] In an embodiment the subtilase variant comprises or consists of the substitution S188C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0265] In an embodiment the subtilase variant comprises or consists of the substitution S188D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0266] In an embodiment the subtilase variant comprises or consists of the substitution S188E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0267] In an embodiment the subtilase variant comprises or consists of the substitution Q191N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0268] In an embodiment the subtilase variant comprises or consists of the substitution N204D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0269] In an embodiment the subtilase variant comprises or consists of the substitution N204V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0270] In an embodiment the subtilase variant comprises or consists of the substitution V205I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0271] In an embodiment the subtilase variant comprises or consists of the substitution Q206C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0272] In an embodiment the subtilase variant comprises or consists of the substitution Q206E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0273] In an embodiment the subtilase variant comprises or consists of the substitution Q206I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0274] In an embodiment the subtilase variant comprises or consists of the substitution Q206K, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0275] In an embodiment the subtilase variant comprises or consists of the substitution Q206T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0276] In an embodiment the subtilase variant comprises or consists of the substitution Q206V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0277] In an embodiment the subtilase variant comprises or consists of the substitution Q206W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0278] In an embodiment the subtilase variant comprises or consists of the substitution Q206L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0279] In an embodiment the subtilase variant comprises or consists of the substitution Y209W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0280] In an embodiment the subtilase variant comprises or consists of the substitution S212A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0281] In an embodiment the subtilase variant comprises or consists of the substitution S212D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0282] In an embodiment the subtilase variant comprises or consists of the substitution S212G, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0283] In an embodiment the subtilase variant comprises or consists of the substitution S212N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0284] In an embodiment the subtilase variant comprises or consists of the substitution S216I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0285] In an embodiment the subtilase variant comprises or consists of the substitution S216T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0286] In an embodiment the subtilase variant comprises or consists of the substitution S216V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0287] In an embodiment the subtilase variant comprises or consists of the substitution L217C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0288] In an embodiment the subtilase variant comprises or consists of the substitution L217M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0289] In an embodiment the subtilase variant comprises or consists of the substitution N218T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0290] In an embodiment the subtilase variant comprises or consists of the substitution M222C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0291] In an embodiment the subtilase variant comprises or consists of the substitution M222R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0292] In an embodiment the subtilase variant comprises or consists of the substitution P225A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0293] In an embodiment the subtilase variant comprises or consists of the substitution T255C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0294] In an embodiment the subtilase variant comprises or consists of the substitution T255E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0295] In an embodiment the subtilase variant comprises or consists of the substitution S256A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0296] In an embodiment the subtilase variant comprises or consists of the substitution S256C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0297] In an embodiment the subtilase variant comprises or consists of the substitution S256D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0298] In an embodiment the subtilase variant comprises or consists of the substitution S256V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0299] In an embodiment the subtilase variant comprises or consists of the substitution S256Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0300] In an embodiment the subtilase variant comprises or consists of the substitution S259D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0301] In an embodiment the subtilase variant comprises or consists of the substitution T260E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0302] In an embodiment the subtilase variant comprises or consists of the substitution T260P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0303] In an embodiment the subtilase variant comprises or consists of the substitution N261C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0304] In an embodiment the subtilase variant comprises or consists of the substitution N261E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0305] In an embodiment the subtilase variant comprises or consists of the substitution N261L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0306] In an embodiment the subtilase variant comprises or consists of the substitution N261M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0307] In an embodiment the subtilase variant comprises or consists of the substitution N261V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0308] In an embodiment the subtilase variant comprises or consists of the substitution N261W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0309] In an embodiment the subtilase variant comprises or consists of the substitution N261Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0310] In an embodiment the subtilase variant comprises or consists of the substitution N261F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0311] In an embodiment the subtilase variant comprises or consists of the substitution L262C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0312] In an embodiment the subtilase variant comprises or consists of the substitution L262E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0313] In an embodiment the subtilase variant comprises or consists of the substitution L262Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

[0314] In one embodiment the subtilase variant comprises or consists of the substitution X9C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0315] In one embodiment the subtilase variant comprises or consists of the substitution X9D in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0316] In one embodiment the subtilase variant comprises or consists of the substitution X9E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0317] In one embodiment the subtilase variant comprises or consists of the substitution X9Q in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0318] In one embodiment the subtilase variant comprises or consists of the substitution X43A in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0319] In one embodiment the subtilase variant comprises or consists of the substitution X43C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0320] In one embodiment the subtilase variant comprises or consists of the substitution X43L in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0321] In one embodiment the subtilase variant comprises or consists of the substitution X43R in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0322] In one embodiment the subtilase variant comprises or consists of the substitution X43W in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0323] In one embodiment the subtilase variant comprises or consists of the substitution X72A in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0324] In one embodiment the subtilase variant comprises or consists of the substitution X72V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0325] In one embodiment the subtilase variant comprises or consists of the substitution X78D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0326] In one embodiment the subtilase variant comprises or consists of the substitution X104F in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0327] In one embodiment the subtilase variant comprises or consists of the substitution X114V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0328] In one embodiment the subtilase variant comprises or consists of the substitution X115T in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0329] In one embodiment the subtilase variant comprises or consists of the substitution X115W in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0330] In one embodiment the subtilase variant comprises or consists of the substitution X120I in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0331] In one embodiment the subtilase variant comprises or consists of the substitution X120T in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0332] In one embodiment the subtilase variant comprises or consists of the substitution X120V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0333] In one embodiment the subtilase variant comprises or consists of the substitution X129D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0334] In one embodiment the subtilase variant comprises or consists of the substitution X147W in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0335] In one embodiment the subtilase variant comprises or consists of the substitution X149C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0336] In one embodiment the subtilase variant comprises or consists of the substitution X149N in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0337] In one embodiment the subtilase variant comprises or consists of the substitution X158E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0338] In one embodiment the subtilase variant comprises or consists of the substitution X160D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0339] In one embodiment the subtilase variant comprises or consists of the substitution X160P in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0340] In one embodiment the subtilase variant comprises or consists of the substitution X161C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0341] In one embodiment the subtilase variant comprises or consists of the substitution X161E in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0342] In one embodiment the subtilase variant comprises or consists of the substitution X163A in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0343] In one embodiment the subtilase variant comprises or consists of the substitution X163D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0344] In one embodiment the subtilase variant comprises or consists of the substitution X182C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0345] In one embodiment the subtilase variant comprises or consists of the substitution X182E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0346] In one embodiment the subtilase variant comprises or consists of the substitution X185C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0347] In one embodiment the subtilase variant comprises or consists of the substitution X185E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0348] In one embodiment the subtilase variant comprises or consists of the substitution X188C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0349] In one embodiment the subtilase variant comprises or consists of the substitution X188D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0350] In one embodiment the subtilase variant comprises or consists of the substitution X188E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0351] In one embodiment the subtilase variant comprises or consists of the substitution X191N in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0352] In one embodiment the subtilase variant comprises or consists of the substitution X204D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0353] In one embodiment the subtilase variant comprises or consists of the substitution X204V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0354] In one embodiment the subtilase variant comprises or consists of the substitution X205I in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0355] In one embodiment the subtilase variant comprises or consists of the substitution X206C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0356] In one embodiment the subtilase variant comprises or consists of the substitution X206E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0357] In one embodiment the subtilase variant comprises or consists of the substitution X206I in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0358] In one embodiment the subtilase variant comprises or consists of the substitution X206K in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0359] In one embodiment the subtilase variant comprises or consists of the substitution X206T in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0360] In one embodiment the subtilase variant comprises or consists of the substitution X206V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0361] In one embodiment the subtilase variant comprises or consists of the substitution X206W in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0362] In one embodiment the subtilase variant comprises or consists of the substitution X206L in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0363] In one embodiment the subtilase variant comprises or consists of the substitution X209W in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0364] In one embodiment the subtilase variant comprises or consists of the substitution X212A in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0365] In one embodiment the subtilase variant comprises or consists of the substitution X212D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0366] In one embodiment the subtilase variant comprises or consists of the substitution X212G in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0367] In one embodiment the subtilase variant comprises or consists of the substitution X212N in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0368] In one embodiment the subtilase variant comprises or consists of the substitution X216I in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0369] In one embodiment the subtilase variant comprises or consists of the substitution X216T in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0370] In one embodiment the subtilase variant comprises or consists of the substitution X216V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0371] In one embodiment the subtilase variant comprises or consists of the substitution X217C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0372] In one embodiment the subtilase variant comprises or consists of the substitution X217M in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0373] In one embodiment the subtilase variant comprises or consists of the substitution X218T in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0374] In one embodiment the subtilase variant comprises or consists of the substitution X222C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0375] In one embodiment the subtilase variant comprises or consists of the substitution X222R in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0376] In one embodiment the subtilase variant comprises or consists of the substitution X225A in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0377] In one embodiment the subtilase variant comprises or consists of the substitution X255C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0378] In one embodiment the subtilase variant comprises or consists of the substitution X255E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0379] In one embodiment the subtilase variant comprises or consists of the substitution X256A in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0380] In one embodiment the subtilase variant comprises or consists of the substitution X256C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0381] In one embodiment the subtilase variant comprises or consists of the substitution X256D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0382] In one embodiment the subtilase variant comprises or consists of the substitution X256V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0383] In one embodiment the subtilase variant comprises or consists of the substitution X256Y in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0384] In one embodiment the subtilase variant comprises or consists of the substitution X259D in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0385] In one embodiment the subtilase variant comprises or consists of the substitution X260E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0386] In one embodiment the subtilase variant comprises or consists of the substitution X260P in any of the polypeptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0387] In one embodiment the subtilase variant comprises or consists of the substitution X261C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0388] In one embodiment the subtilase variant comprises or consists of the substitution X261E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0389] In one embodiment the subtilase variant comprises or consists of the substitution X261L in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0390] In one embodiment the subtilase variant comprises or consists of the substitution X261M in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0391] In one embodiment the subtilase variant comprises or consists of the substitution X261V in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0392] In one embodiment the subtilase variant comprises or consists of the substitution X261W in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0393] In one embodiment the subtilase variant comprises or consists of the substitution X261Y in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0394] In one embodiment the subtilase variant comprises or consists of the substitution X261F in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0395] In one embodiment the subtilase variant comprises or consists of the substitution X262C in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0396] In one embodiment the subtilase variant comprises or consists of the substitution X262E in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0397] In one embodiment the subtilase variant comprises or consists of the substitution X262Q in the polypeptide of any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.

[0398] In another preferred embodiment of the present invention, the variant is a polypeptide having a substitution according to the present invention and having an amino acid sequence that is at least 60% identical to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

[0399] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution S9C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0400] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X9D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0401] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X9E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0402] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X9Q compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0403] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X43A compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0404] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X43C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0405] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X43L compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0406] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X43R compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0407] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X43W compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0408] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X72A compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0409] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X72V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0410] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X78D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0411] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X104F compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0412] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X114V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0413] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X115T compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0414] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X115W compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0415] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X120I compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0416] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X120T compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0417] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X120V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0418] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X129D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0419] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X147W compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0420] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X149C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0421] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X149N compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0422] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X158E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0423] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X160D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0424] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X160P compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0425] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X161C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0426] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X161E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0427] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X163A compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0428] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X163D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0429] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X182C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0430] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X182E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0431] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X185C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0432] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X185E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0433] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X188C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0434] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X188D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0435] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X188E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0436] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X191 N compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0437] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X204D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0438] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X204V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0439] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X205I compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0440] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0441] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0442] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206I compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0443] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206K compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0444] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206T compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0445] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0446] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206W compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0447] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X206L compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0448] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X209W compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0449] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X212A compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0450] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X212D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0451] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X212G compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0452] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X212N compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0453] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X216I compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0454] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X216T compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0455] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X216V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0456] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X217C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0457] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X217M compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0458] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X218T compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0459] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X222C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0460] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X222R compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0461] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X225A compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0462] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X255C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0463] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X255E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0464] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X256A compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0465] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X256C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0466] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X256D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0467] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X256V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0468] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X256Y compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0469] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X259D compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0470] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X260E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0471] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X260P compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0472] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0473] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0474] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261L compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0475] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261M compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0476] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261V compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0477] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261W compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0478] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261Y compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0479] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X261F compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0480] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X262C compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0481] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X262E compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0482] In an embodiment the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the subtilase variant comprises or consists of the substitution X262Q compared to any of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.

[0483] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 206 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 206 of the polypeptide of SEQ ID NO: 2 is substituted with C, E, I, K, T, V, L or W, preferably with L, C or W. In another aspect, the variant comprises or consists of the substitution Q206L, Q206W or Q206C in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0484] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 262 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 262 of the polypeptide of SEQ ID NO: 2 is substituted with C, E or Q, preferably with E or C. In another aspect, the variant comprises or consists of the substitution L262E or L262C in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0485] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 225 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 225 of the polypeptide of SEQ ID NO: 2 is substituted with A. In another aspect, the variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0486] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 9 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 9 of the polypeptide of SEQ ID NO: 2 is substituted by C, D, E or Q, preferably by E. In another aspect, the variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0487] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 209 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 209 of the polypeptide of SEQ ID NO: 2 is substituted by L or W, preferably by W. In another aspect, the variant comprises or consists of the substitution Y209W in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0488] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 212 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 212 of the polypeptide of SEQ ID NO: 2 is substituted by A, D, G or N, preferably by D, G or N. In another aspect, the variant comprises or consists of the substitution S212D, S212G or S212N in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0489] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 261 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 261 of the polypeptide of SEQ ID NO: 2 is substituted by C, E, L, M, V, W, Y or F, preferably by W. In another aspect, the variant comprises or consists of the substitution N261W in the polypeptide of SEQ ID NO: 1 (BPN' numbering).

[0490] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 206 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 206 of the polypeptide of SEQ ID NO: 2 is substituted with C, E, I, K, T, V, L or W, preferably with L, C or W. In another aspect, the variant comprises or consists of the substitution Q206L, Q206W or Q206C in the polypeptide of SEQ ID NO: 2 (BPN' numbering).

[0491] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 262 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 262 of the polypeptide of SEQ ID NO: 2 is substituted with C, E or Q, preferably with E or C. In another aspect, the variant comprises or consists of the substitution Y262E or Y262C in the polypeptide of SEQ ID NO: 2 (BPN' numbering).

[0492] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 225 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 225 of the polypeptide of SEQ ID NO: 2 is substituted with A. In another aspect, the variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 2 (BPN' numbering).

[0493] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 9 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 9 of the polypeptide of SEQ ID NO: 2 is substituted by C, D, E or Q, preferably by E. In another aspect, the variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 2 (BPN' numbering).

[0494] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 209 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 209 of the polypeptide of SEQ ID NO: 2 is substituted with W. In another aspect, the variant comprises or consists of the substitution L209W in the polypeptide of SEQ ID NO: 2 (BPN' numbering).

[0495] In a preferred aspect of the invention, the subtilase variant of the invention comprises or consists of a substitution at the position corresponding to position 261 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at the position corresponding to position 261 of the polypeptide of SEQ ID NO: 2 is substituted by C, E, L, M, V, W or Y, preferably by W. In another aspect, the variant comprises or consists of the substitution F261W in the polypeptide of SEQ ID NO: 2 (BPN' numbering).

[0496] The inventors have demonstrated that each of these mutations selected from the following list, consisting of: S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H12 0I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161 E. S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S 212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M22 2R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E, and L262Q. This stabilizing effect increases as more stabilizing mutations are added.

[0497] Therefore, another aspect of the invention relates to a subtilase variant having protease activity, wherein the variant comprises two substitutions selected from the list consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C , S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204 D. N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S21 2A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P2 256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to a corresponding position of the polypeptide of SEQ ID NO: 2.

[0498] Another preferred embodiment of the present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 1 when measured in the accelerated storage stability assay of Example 3 herein, wherein the variant comprises two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G115W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191N, N204D, N204V, V205I, Q206C, Q206 I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261C, N261E, N261L, N261V, N261Y, N261W, L262C, L262E and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% identity to the amino acid sequence of SEQ ID NO: 1.

[0499] Another preferred embodiment of the present invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO: 1 when measured in the accelerated storage stability assay of Example 3 herein, wherein the variant comprises two or more substitutions selected from the group consisting of S9E, N43R, H120V, Q182E, Q191N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261E, N261W and L262E, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% identity to the amino acid sequence of SEQ ID NO: 1.

[0500] In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or compared to the polypeptide of SEQ ID NO: 2. In a preferred embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or compared to the polypeptide of SEQ ID NO: 2, and equivalent or improved wash performance.

[0501] In one aspect of the invention, the subtilase variant comprises, or consists of, one or more of the substitutions listed in Table 2, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60% identity to the amino acid sequence of SEQ ID NO: 1. In one aspect of the invention, the subtilase variant comprises an amino acid sequence comprising one or more substitutions compared to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, wherein the substitution(s) are selected from one or more of the substitutions listed in Table 2, and wherein the positions correspond to the corresponding positions of the polypeptide of SEQ ID NO: 2.

[0502] Table 2: Subtilase variants SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:4、SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12 + one or more mutations listed below

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

[0521]

[0522]

[0523] In another aspect of the invention, the subtilase variant of the invention comprises three of the substitutions selected from the following list, the list consisting of: S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H1 20T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163 A. S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N204V, V 205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S21 2D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, particularly improved storage stability, compared to the parent subtilase. In a preferred embodiment, the subtilase variant has improved stability, particularly improved storage stability, and equivalent or improved wash performance compared to the parent protease.

[0524] Preferred variants include variants comprising the following mutations compared to any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12:

[0525] N76D+S9E+L262E

[0526] N76D+P225A+S259D

[0527] N76D+S212D+P225A

[0528] N76D+N43R+L262E

[0529] N76D+S212D+S259D

[0530] N76D+Q206C+Y209W

[0531] N76D+V205I+Q206L

[0532] N76D+P131*+S212D

[0533] N76D+P131*+S259D

[0534] N76D+V205I+Q206I

[0535] N76D+G160P+S161E

[0536] N76D+N204D+Q206L

[0537] N76D+V205I+Q206V

[0538] N76D+A194P+Q206E

[0539] N76D+P131*+P225A

[0540] N76D+N204D+Q206I

[0541] N76D+N204D+V205I

[0542] N76D+N204D+Q206V

[0543] N76D+N204D+Q206W

[0544] N76D+N261W+L262E

[0545] N76D+N261L+L262E

[0546] N76D+G160P+S161Y

[0547] N76D+N261E+L262E

[0548] N76D+N261V+L262E

[0549] N76D+Q206L+Y209W

[0550] N76D+N261Y+L262E

[0551] N76D+V205I+Q206W

[0552] N76D+G160D+S161E

[0553] N76D+V205I+Q206E

[0554] N76D+Q206L+S256D

[0555] N76D+G115T+H120T

[0556] N76D+G160D+S161Y

[0557] N76D+N18S+V205I

[0558] N76D+A194P+M222S

[0559] N76D+Y209W+S256D

[0560] N76D+N18S+Q206E

[0561] N76D+Y209W+S256C

[0562] N76D+G115T+H120V

[0563] N76D+T255E+S256D

[0564] N76D+G115T+H120I

[0565] N76D+T255Q+S256D

[0566] N76D+*99aE+S212D+N261D

[0567] N76D+T255E+S256Y+T260E

[0568] N76D+T255E+S256Y+T260P

[0569] N76D+T255Q+S256Y+T260E

[0570] N76D+T255Q+S256Y+T260P

[0571] N76D+T255E+S256A+T260P

[0572] N76D+T255Q+S256A+T260E

[0573] N76D+T255Q+S256A+T260P

[0574] N76D+A158E+G160D+S161E

[0575] N76D+A158E+G160D+S161H

[0576] N76D+A158E+G160D+S161Y

[0577] N76D+A158E+G160P+S161E

[0578] N76D+A158E+G160P+S161H

[0579] N76D+A158E+G160P+S161Y

[0580] N76D+N204D+V205I+Q206I

[0581] N76D+N204D+V205I+Q206L

[0582] N76D+N204D+V205I+Q206V

[0583] N76D+N204D+V205I+Q206W

[0584] N76D+N204D+V205L+Q206I

[0585] N76D+N204D+V205L+Q206L

[0586] N76D+N204D+V205L+Q206V

[0587] N76D+N204D+V205L+Q206W

[0588] N76D+T255E+S256D+T260E

[0589] N76D+T255E+S256D+T260P

[0590] N76D+T255Q+S256D+T260E

[0591] N76D+T255Q+S256D+T260P

[0592] N76D+P129D+A158E+Q191N

[0593] N76D+P129D+G160D+S161E

[0594] N76D+P129D+G160D+S161H

[0595] N76D+P129D+G160D+S161Y

[0596] N76D+P129D+G160P+S161H

[0597] N76D+G160P+S161Y+Q191N

[0598] S9E+N43R+N76D+L262E

[0599] S9E+N76D+S212D+S259D

[0600] N43R+N76D+S212D+S259D

[0601] S9E+N76D+S212D+N261D

[0602] S9E+N76D+S212D+N261D

[0603] N76D+S212D+S259D+N261D

[0604] S9E+G61E+N76D+L262E

[0605] G61E+N76D+Q206L+L262E

[0606] N76D+*99aE+G195E+K235L

[0607] N76D+*99aE+H120D+G195E

[0608] S9E+N76D+*99aE+L262E

[0609] N76D+*99aE+H120D+K235L

[0610] N76D+*99aE+A194P+Q206E

[0611] N43R+N76D+*99aE+L262E

[0612] N18S+N76D+V205I+Q206E

[0613] N76D+Q206C+Y209W+S256D

[0614] N76D+Q206L+Y209W+S256D

[0615] N76D+Q206L+Y209W+S256C

[0616] G61E+N76D+A194P+V205I+Q206E

[0617] S9E+N43R+N76D+A194P+L262E

[0618] S9E+N43R+N76D+S212D+S259D

[0619] S9E+N43R+G61E+N76D+L262E

[0620] S9E+N76D+Q206L+Y209W+S256D

[0621] G61E+N76D+Q206L+Y209W+S256D

[0622] S9E+G61E+N76D+Q206L+Y209W

[0623] N76D+*99aE+S212D+S259D

[0624] N76D+*99aE+P131*+S259D

[0625] S9E+N76D+*99aE+S212D+S259D

[0626] N43R+N76D+*99aE+S212D+S259D

[0627] S9E+N76D+*99aE+S212D+N261D

[0628] S212D+N76D+*99aE+P131*

[0629] *35aD+N76D+H120D+G195E+*275aF

[0630] N43R+N76D+Q206L+Y209W+S256D

[0631] N76D+*99aE+H120D+G195E+K235L

[0632] N76D+*99aE+Q206L+Y209W+S256D

[0633] N76D+*99aE+Q206L+Y209W+S256D

[0634] S9E+N43R+N76D+*99aE+L262E

[0635] N76D+A158E+G160D+S161E+Q191N

[0636] N76D+P129D+A158E+G160D+S161E

[0637] N76D+P129D+A158E+G160D+S161E

[0638] N76D+P129D+A158E+G160D+S161E

[0639] N76D+P129D+A158E+G160D+S161E

[0640] N76D+A158E+G160D+S161H+Q191N

[0641] N76D+P129D+A158E+G160D+S161H

[0642] N76D+A158E+G160D+S161Y+Q191N

[0643] N76D+P129D+A158E+G160D+S161Y

[0644] N76D+A158E+G160P+S161E+Q191N

[0645] N76D+P129D+A158E+G160P+S161E

[0646] N76D+P129D+A158E+G160P+S161Y

[0647] N76D+N204D+V205I+Q206I+S216V

[0648] N76D+N204D+V205I+Q206L+S216V

[0649] N76D+Q182E+N204D+V205I+Q206L

[0650] N76D+S99D+H120N+P131*+Q206E+S212D

[0651] N76D+S99D+H120N+P131*+A194P+Q206E

[0652] N76D+S99D+H120N+P131T+A194P+Q206E

[0653] A15T+N76D+H120N+P131*+V205I+Q206E

[0654] A15T+N76D+H120I+P131T+V205I+Q206E

[0655] S9E+N43R+N76D+Q206H+S212D+S259D

[0656] *35aD+N76D+H120D+G195E+K235L+*275aR

[0657] S9E+G61E+N76D+Q206L+Y209W+S256D

[0658] S9E+N43R+I72A+N76D+A194P+L262E

[0659] S9E+N43R+N76D+Q206L+Y209W+S256D

[0660] S9E+N43R+N76D+*99aE+A194P+L262E

[0661] S9E+N43R+N76D+*99aE+S212D+S259D

[0662] N76D+P129D+A158E+G160D+S161E+Q191N

[0663] N76D+P129D+A158E+G160D+S161H+Q191N

[0664] N76D+P129D+A158E+G160D+S161Y+Q191N

[0665] N76D+P129D+A158E+G160P+S161E+Q191N

[0666] N76D+P129D+A158E+G160P+S161H+Q191N

[0667] N76D+Q182E+N204D+V205I+Q206I+S216V

[0668] N76D+Q182E+N204D+V205I+Q206L+S216V

[0669] 35aD+N76D+H120D+G195E+K235L+*275aH

[0670] S9R+A15T+N76D+A194P+Q206E+Q245R+N261D

[0671] S9R+A15T+G61E+N76D+A194P+Q245R+N261D

[0672] S9E+N43R+N76D+A158E+G160P+A194P+L262E

[0673] S9E+N43R+N76D+*99aE+Q206H+S212D+S259D

[0674] S9E+N43R+N76D+P131*+Q206L+Y209W+S256D

[0675] S9E+N43R+I72A+N76D+A158E+G160P+A194P+L262E

[0676] 35aD+N76D+H120D+G195E+K235L+*275aH+*275bH

[0677] A15T+G61D+N76D+S99D+H120N+P131*+Q206E+S212D

[0678] S9R+A15T+N76D+S99D+A194P+V205I+Q206E+Q245R+N261D

[0679] *35aD+N76D+H120D+G195E+K235L+*275aH+*275bH+*275cH

[0680] A15T+N76D+S99D+H120D+A194P+V205I+S212D+Q245R+N261D

[0681] T58Y+N76D+S99D+H120N+P131*+A194P+Q206E+S212D+S259D

[0682] A15T+N76D+S99D+H120N+A194P+Q206E+Q245R+N261D+L262Y

[0683] S9E+N43R+I72A+N76D+A158E+G160P+A194P+L262E+*275aH+*275bH

[0684] A15T+G61D+N76D+H120I+P131*+A194P+Q206L+S212D+Q245R+S259D

[0685] A15T+G61D+N76D+H120I+P131*+A194P+Q206V+S212D+Q245R+S259D

[0686] S9E+N43R+I72A+N76D+Q137H+S141H+R145H+A158E+G160P+A194P+L262E, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.

[0687] In another aspect of the invention, the subtilase of the invention comprises four or five or six or seven or eight of the substitutions selected from the list consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161 E. S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N2 04V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225 A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E and L262Q, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or compared to the polypeptide of SEQ ID NO: 2. In a preferred embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or compared to the polypeptide of SEQ ID NO: 2, and equivalent or improved wash performance.

[0688] A particular embodiment of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variants comprise one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161 E. S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N2 04V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225 A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E, and L262Q, wherein each position corresponds to a position of the polypeptide of SEQ ID NO: 2, wherein the variant comprises any additional mutation selected from the list consisting of Q2R, W6L, W6I, I8C, I8H, S9R, A15T, N18S, S24H, * 35aD, A48H, S49T, G53A, G53L, T58Y, G61E, G61D, N76D, S99D, * 99aE, V104P, V104T, V104Y, N117H, H120N, H120D, P131 * , Q137H, S141H, R145H, V149Q, S161Y, I162L, N184D, A194P, A194D, A194E, V2 05L, M222N, P225S, K235L, N238H, V244H, N248H, T255Q, T260A, N261D, N261R, *275aR, * 275aF, * 275aH, * 275bH and * 275cH.

[0689] The subtilase variant may further comprise one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0690] Thus, in further embodiments of the invention, the subtilase variants described in Tables 1 and 2 further comprise, or consist of, one or more of the following substitutions in the polypeptide of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12: S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In an embodiment the subtilase variant has improved stability compared to the parent subtilase or compared to the polypeptide of SEQ ID NO: 1, in particular improved stability in storage.

[0691] A particular embodiment of the invention relates to subtilase variants having protease activity and at least 25% improved stability compared to the subtilase having SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variants comprise one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161 E. S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191N, N204D, N2 04V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225 A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261C, N261E, N261L, N261M, N261V, N261Y, N261W, N261F, L262C, L262E, and L262Q, where each position corresponds to SEQ 24R, S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K, and Q245R (numbering according to SEQ ID NO: 2).

[0692] In one embodiment of the invention the subtilase variant comprises or consists of one of the substitutions S9C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0693] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S9D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0694] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S9E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0695] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S9Q and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0696] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N43A and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0697] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N43C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0698] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N43L and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0699] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N43R and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0700] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N43W and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0701] In one embodiment of the invention the subtilase variant comprises or consists of substitution I72A and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0702] In one embodiment of the invention the subtilase variant comprises or consists of the substitution I72V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0703] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S78D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0704] In one embodiment of the invention the subtilase variant comprises or consists of the substitution A114V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0705] In one embodiment of the invention the subtilase variant comprises or consists of the substitution G115T and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0706] In one embodiment of the invention the subtilase variant comprises or consists of the substitution G115W and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0707] In one embodiment of the invention the subtilase variant comprises or consists of the substitution H120I and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (encoded according to SEQ ID NO: 4).

[0708] In one embodiment of the invention the subtilase variant comprises or consists of the substitution H120T and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0709] In one embodiment of the invention the subtilase variant comprises or consists of the substitution H120V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0710] In one embodiment of the invention the subtilase variant comprises or consists of the substitution V147W and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0711] In one embodiment of the invention the subtilase variant comprises or consists of the substitution V149C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0712] In one embodiment of the invention the subtilase variant comprises or consists of the substitution V149N and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0713] In one embodiment of the invention the subtilase variant comprises or consists of the substitution A158E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0714] In one embodiment of the invention the subtilase variant comprises or consists of the substitution G160D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0715] In one embodiment of the invention the subtilase variant comprises or consists of the substitution G160P and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0716] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S161C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0717] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S161E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0718] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S163A and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0719] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S163D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0720] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q182C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0721] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q182E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0722] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N185C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0723] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N185E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0724] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q188C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0725] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q188D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0726] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q188E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0727] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q191N and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0728] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N204D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0729] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N204V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0730] In one embodiment of the invention the subtilase variant comprises or consists of the substitution V205I and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0731] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0732] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0733] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206I and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0734] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206K and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0735] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206T and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0736] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0737] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206W and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0738] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Q206L and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0739] In one embodiment of the invention the subtilase variant comprises or consists of the substitution Y209W and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0740] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S212A and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0741] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S212D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0742] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S212G and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0743] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S212N and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0744] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S216I and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0745] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S216T and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0746] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S216V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0747] In one embodiment of the invention the subtilase variant comprises or consists of the substitution M222C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0748] In one embodiment of the invention the subtilase variant comprises or consists of the substitution M222R and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0749] In one embodiment of the invention the subtilase variant comprises or consists of the substitution P225A and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0750] In one embodiment of the invention the subtilase variant comprises or consists of the substitution T255C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0751] In one embodiment of the invention the subtilase variant comprises or consists of the substitution T255E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0752] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S256A and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0753] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S256C and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0754] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S256D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0755] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S256V and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0756] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S256Y and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0757] In one embodiment of the invention the subtilase variant comprises or consists of the substitution S259D and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0758] In one embodiment of the invention the subtilase variant comprises or consists of the substitution T260E and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0759] In one embodiment of the invention the subtilase variant comprises or consists of the substitution T260P and one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101R, S101K, S101N, S101M, S101E, S101D, S101L, S101I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).

[0760] In one embodiment of the invention the subtilase variant comprises or consists of the substitution N261C and one or more substitutions selected from the grou...

Claims

1. A subtilase variant of a subtilase parent as shown in SEQ ID NO: 1, wherein the variant has at least 25% improved storage stability in a liquid detergent compared to the subtilase parent, wherein the substitutions of the variant relative to the subtilase parent are N76D+N43R+L262E, wherein the position numbering is according to SEQ ID NO:

2.

2. A detergent composition comprising a variant according to claim 1 and one or more detergent components.

3. The detergent composition according to claim 2, further comprising one or more additional enzymes selected from the group consisting of: Proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidases, haloperoxygenases, catalases and mannanases, or any mixtures thereof.

4. A detergent composition according to claim 2 or 3 in the form of a bar, a uniform tablet, a tablet with two or more layers, a bag with one or more chambers, a regular or compressed powder, a granulate, a paste, a gel, or a regular, compressed or concentrated liquid, e.g. a liquid detergent.

5. Use of a variant according to claim 1 or a detergent composition according to any one of claims 2 to 3 in a cleaning process.

6. Use according to claim 5, wherein the cleaning process is laundry or hard surface cleaning.

7. A method for producing a subtilase variant having protease activity, the method comprising a. introducing the substitution N76D+N43R+L262E into the subtilase parent as shown in SEQ ID NO: 1, wherein the position numbering is according to SEQ ID NO: 2, and b. recovering the variant; Wherein the variant has at least 25% improved storage stability in a liquid detergent compared to said subtilase parent.

Images